Neurones stock: fair value
NRO.PAThe fair value of Neurones under our model is $48.18, the price is 6% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Fairly valuedIn our model the price counts as cheap below $37.06 and expensive above $68.83 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $57.14 (cash-flow model) and $39.23 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.8%. At 8.8% the fair value would be $43.39, at 6.8% it would be $55.38.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (18.8).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 2.8%. Discounted at 7.8% (floor: government bond yield 2.8% plus 5 percentage points, since beta 1.01 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $57.14 per share: free cash flow for the next ten years, each year discounted to today at 7.8%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 7.8%) |
|---|---|---|---|---|
| 2026 | $78.94M | extrapolated at 5.9% | 0.9278 | $73.25M |
| 2027 | $82.85M | extrapolated at 5.0% | 0.8608 | $71.32M |
| 2028 | $86.42M | extrapolated at 4.3% | 0.7987 | $69.02M |
| 2029 | $89.74M | extrapolated at 3.8% | 0.7410 | $66.5M |
| 2030 | $92.9M | extrapolated at 3.5% | 0.6876 | $63.88M |
| 2031 | $95.97M | extrapolated at 3.3% | 0.6379 | $61.22M |
| 2032 | $98.99M | extrapolated at 3.2% | 0.5919 | $58.59M |
| 2033 | $101.99M | extrapolated at 3.0% | 0.5492 | $56.01M |
| 2034 | $105.01M | extrapolated at 3.0% | 0.5095 | $53.5M |
| 2035 | $108.06M | extrapolated at 2.9% | 0.4727 | $51.08M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $624.38M |
| Terminal value: cash flow 2035 × (1 + 2.8%) / (7.8% − 2.8%) | $2.22B |
| Present value of terminal value (× 0.4727) | $1.05B |
| Equity value (sum plus present value of terminal value) | $1.67B |
| Shares (diluted) | 29.31M |
| Value per share (equity value divided by shares) | $57.14 |
| Earnings per share, last twelve months | $2.09 |
| × 18.8 (industry P/E) | $39.23 |
| Fair value (average of both parts) | $48.18 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 17 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.